摘要目的探讨琥珀散对卵巢囊肿患者血清肿瘤抗原125（CA125）、糖类抗原CA199（CA199）水平的影响，并分析其临床疗效。方法90例卵巢囊肿患者根据治疗方法分为两组：采用大黄庶虫丸口服治疗45例（大黄庶虫丸组），琥珀散组治疗45例（琥珀散组），2个月为1个疗程，均治疗一个疗程。另外选取女性健康体检者30例（对照组）。采用化学发光法检测正各组血清CA125、CA199水平，B超检测90例卵巢囊肿患者治疗前后囊肿直径并分析临床疗效。结果大黄庶虫丸组、琥珀散组治疗前血清CA125、CA199水平显著高于对照组（ P ＜0．01）；治疗后大黄庶虫丸组、琥珀散组血清CA125、CA199水平均下降，但琥珀散组血清CA125、CA199水平显著低于大黄庶虫丸组（ P ＜0．05）。琥珀散组治疗后囊肿直径显著小于大黄庶虫丸组（P ＜0．05），其总有效率显著高于大黄庶虫丸组（P ＜0．05）。结论琥珀散可显著降低卵巢囊肿患者的血清CA125、CA199水平，显著改善患者临床症状，疗效满意，值得临床推广。
Abstract：[Objective]To explore the effects of addition‐subtraction amber powder on serum levels of CA125 and CA199 in patients with ovarian cysts .[Methods]A total of 90 patients with ovarian cysts were di‐vided into control and treatment groups .And another 30 female healthy subjects were selected into normal group .The control group received Dahuang Zhechong pill ,while the treatment group by addition‐subtraction amber powder .All treatments lasted 2 months .The serum levels of CA125 and CA199 were detected by chemiluminescent detection in normal ,control and treatment groups before and after treatment .Type B ultra‐sound was used to detect the diameter of cysts in control and treatment groups before and after treatment . Then clinical efficacies were analyzed .[Results]Before treatment ,the serum levels of CA125 and CA199 were both much higher than those of normal group ( P < 0 .05) .After treatment ,the serum levels of both de‐creased in two groups .However ,the decrease of treatment group was more dramatic ( P<0 .05) .The diam‐eter of cysts in treatment group was much smaller than that of control group ( P<0 .05) .And its overall effi‐cacy was significantly higher than that of control group ( P<0 .05) .[Conclusion]Addition‐subtraction amber powder can decrease significantly the serum levels of CA125 and CA199 to improve clinical symptoms .It is ef‐ficacious for ovarian cysts and worthy of wider applications .
引用本文:
章霞. 琥珀散对卵巢囊肿患者血清CA125、CA199水平的影响及疗效分析[J]. 医学临床研究, 2015, 32(1): 102-103,106.
ZHANG Xia. Effects of Addition-subtraction Amber Powder on Serum Levels of CA125 and CA199 in Patients with Ovarian Cysts. JOURNAL OF CLINICAL RESEARCH, 2015, 32(1): 102-103,106.
2015, Vol. 32 
